MeiraGTx Holdings plc

NASDAQ:MGTX   12:04:13 PM EDT
14.29
+0.29 (+2.07%)
Products, Regulatory

MeiraGTx Announces Positive Preliminary Data from the Phase 1 Clinical Trial of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

Published: 12/07/2021 13:06 GMT
MeiraGTx Holdings plc (MGTX) - Meiragtx Announces Positive Preliminary Data From the Aquax Phase 1 Clinical Trial of Aav-haqp1 for the Treatment of Grade 2/3 Radiation-induced Xerostomia.
Meiragtx - Clinically Meaningful Improvements in Xerostomia Symptoms and Disease Burden Reported in Two Validated Patient Reported Outcome Measures.
Meiragtx Holdings Plc - Aav-haqp1 Appears Safe and Well-tolerated at Each Dose Tested.